Aliment Pharmacol Ther 2011; 33: 946–953 Summary Background Adalimumab is
efficacious therapy for adults with Crohn's disease (CD). Aim To summarise the United …

Background: Anti tumor necrosis factor alpha (TNFα) agents have become widely used in
pediatric inflammatory bowel disease (IBD). So far, only few studies examined the long-term …

The incidence of inflammatory bowel disease (IBD) has increased steadily worldwide, both
in adult and in children; approximately 25% of IBD patients are diagnosed before the age of …

Background The PAILOT trial was a randomized controlled trial aimed to evaluate proactive
vs reactive therapeutic drug monitoring in children with Crohn's disease (CD) treated with …

Abstract Background and Aims: There is growing evidence that in Crohn's disease the
achievement and maintenance of mucosal healing (MH) through anti-TNFα antibodies may …

Background: Infliximab (IFX) is efficacious for induction and maintenance of remission in
pediatric patients with moderate-to-severe inflammatory bowel disease (IBD). It has …

Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis,
are chronic relapsing and remitting diseases of the bowel, with an unknown etiology and …

A subset of children with psoriasis will experience severe, debilitating, life-altering disease
at some point. As with any severe disease, the exact approach will vary by the individual …

Objectives: European Crohn's Colitis Organization (ECCO) and the European Society of
Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) guidelines recommend …

Purpose To determine the long-term efficacy of the anti-tumor necrosis factor (TNF) agents,
infliximab (IFX) and adalimumab (ADA), in pediatric luminal Crohn's disease (CD) by …